OCM for BreCeCan Series Conferences

Organizing Committee

Biography

Dr. Mosavi-Jarrahi received his Ph.D. in epidemiology from the University of Texas in 1996. Upon graduation, He began his post-doctoral research at the University of Texas Health Science Center. In 1998, he joined the Cancer Institute in Tehran, Iran, working as a research associate and at the same time he received a joint appointment as an assistant professor at the Medical School, Shahid Beheshti University of Medical Sciences Tehran, Iran. In 2011, he joined the Faculty of Health Sciences (FHS), Simon Fraser University as an adjunct professor of epidemiology. He has published more than 60 papers in peer-reviewed journals and received several grants from different funding agencies such as Terry Fox Foundation (international), World Health Organization. He is a founding member of the Iranian Epidemiological Association and served as its first general secretary for two terms. He is a member of several scientific journals’ editorial board. In July 2016, he was appointed as the Editor-in-Chief of the Asia Pacific Journal of Cancer Prevention. In April 2018, Dr. Mosavi jarrah was appointed as the President of Asian Pacific Organization for Cancer Prevention (APOCP) for a duration of two years.

Research Interest

Biography

Professional Activities for IASP:
• Former International Council member in IASP, 2008-2014.
• Coordinator of the Pain School Project (IASP project) for post graduate degrees in pain, aesthesia, and physical medicine, 2011-2018.
• Founder of the Egyptian Society for the Management of Pain, 1982; President (ESMP, IASP Chapter), 2009-2015.
• Member in the Developing Countries Working Group, 2008-2012.
• Winner of IASP grant for pain education in developing countries twice:
i. Pain education in remote location for the G.P in Egypt, 2006.
ii. Opioids Legislations for the Pharmacists and Pharmacy Students in Egypt, 2009
• Representative of IASP in the following meetings, 2009-2015:
i. Official visiting professor representing IASP in, and congresses in pain in Bangladesh, 2015, , Albania, 2013, Nigeria, 2011.
ii. WHO-EMRO for management of cancer pain, in Fez, Morocco, 2009.
• Pushed the establishment of some IASP chapters (Libya, Ghana and Jordan), and national pain societies (Sudan, Saudi Arabia and Iraq) in Africa and Middle East, 2006-2011.
• Co-designer of the pain questionnaire and pain survey done by the Developing Countries Working Group, 2008.
• Member in the taskforce of the IASP for pain education in developing countries, 1999-2012.
• Regular attendant of the IASP World congress on Pain since 1984 – 2014 except, 1996 and 2016
• Member of the International Association for the Study of Pain (IASP), 1984 to date.

Research Interest

Biography

Dr. Mahir Jallo, Clinical Professor of Medicine, Head of Department & Consultant, Internal Medicine - Diabetes & Endocrinology in Gulf Medical University – UAE & Faculty in the Canadian Academy of Natural Health – Toronto – Canada. Granted his MBChB from Mosul Medical College - IRAQ, his postgraduate Board Certification in Internal Medicine CABM from the Arab Board, his Fellowship of American College of Endocrinology FACE, & and Diploma in Dyslipidemia from Boston University School of Medicine from USA . Invited speaker in many National & International conferences & CME programs. Organizer of the annual GMU Diabetes & Endocrinology Conference in UAE since 2012. Member of organizing committees for many international conferences in US & Europe. Editorial Board Member & reviewer for many international Diabetes & Endocrinology journals, with many publications in medical periodicals and medical conferences abstract & Active Principle Investigator in many National & International Clinical studies. Member of many national & international medical societies & associations, AACE, EASD, ISPAD, ESE & European Atherosclerosis Society. Awarded twice A Special Honor & Award in recognition of the exemplary achievements in the field of Internal Medicine & Endocrinology and for the invaluable service to the community.

Research Interest

Biography

Brianne Joseph is an award-winning Private Investigator, Best-selling author, keynote speaker, and breast cancer survivor. She is the Owner at Sly Fox Investigations - an all female, six-figure Private Investigation agency, owner of Punk Azz Cancer- a breast cancer empowerment brand, and is author to inspirational book ‘Punk Azz Cancer, How Dare You!’ A recognized leader, Brianne was previously the Region II Director of the Louisiana Private Investigators Association, was named the 2011 'Investigator Of The Year ' by the National Association of Investigative Specialists, and was awarded 2017 ‘Best Private Investigator in New Orleans’ by Expertise. Brianne is also the State Leader for the Young Survival Coalition- an organization that provides resources to breast cancer survivors under 40.

Biography

Dr. Yan-Gao Man holds a Medical degree in Western Medicine, Master degree in Microbiology, and PhD in Cell Biology/Anatomy. He completed postdoctoral training in Cancer Biology at National Cancer Institute, NIH, USA. Dr. Man served as the Director of Gynecological and Breast Research Laboratory of Armed Forces Institute of Pathology and American Registry of Pathology for 16 years. Currently, he serves as Adjunct Distinguished Scientist at Hackensack University Medical Center, NJ, USA, the Vice President for Research & Collaboration at South Hospital of Nanjing, China, visiting professor of China Key Laboratory of Sub-health Intervention, the Editor-in-chief for several international medical journals, and the Chairman of Board Directors and Secretary General of International Union for Difficult-to-treat Diseases (www.iudd.org; www.canceraging.org; www.canceraging.org/2016/). Dr. Man has authored and co-authored over 250 published articles and abstracts in the cancer field, 46 non-scientific articles, 4 book chapters, and 14 novel protocols for molecular and immunohistochemical assays. Dr. Man’s medical practice and research are primarily focused on the mechanism of cancer invasion and metastasis. He is the originator of most updated hypotheses for cancer invasion and metastasis; his hypothesis of cancer invasion has been recognized as “more compatible with existing experimental evidence than the traditional “protoelytic enzyme” theory” [Pandey PR et al. Front Biosci. 15: 226–236, 2011], and his hypothesis of cancer metastasis is the only one that can reasonably explain all major steps of cancer metastasis among all existing theories.

Research Interest

Biography

Dr. Sawsan A. S. Al Madhi has more than 14 years progressive
leadership skills and experience in strategy, operations and
administration for the not-profit charitable sector. Currently
working with one of the most reputable charities in the UAE as the
Director General for Friends of Cancer Patients, Dr. Sawsan’s role is
to supervise the continuing refinement and expansion of the
organizational objectives which include: providing high quality
services, organizing fundraising activities, developing
,planning and executing nationwide awareness
programs and campaigns through collaboration with
a vast network of national and international,
governmental and private sector organizations.

Research Interest

Biography

Dr. Marveh Rahmati is currently working as an Assistant professor of Cancer Biology Research Center, Tehran University of Medical Sciences, Tehran, Iran. She obtained her PhD in medical biotechnology from Tabriz University of Medical Sciences, Iran and spent her Sabbatical research in national university of Ireland, Galway. Dr. Marveh Rahmati research is mainly focused in mechanisms of cancer drug resistance through apoptosis or autophagy pathways, study of nanoparticles in targeted therapy, epidemiology and epigenetic study of cancers in Iran. In 2008, she received her master’s degree in the field of microbiology from Alzahra university of Tehran, Iran. She has won “the young scientist awards” in 2009 from Iranian Society of Microbiology, “the best researcher awards” and “top students award” in 2008 from Alzahra university.
Dr. Rahmati published 18 articles in national and international journals, one-chapter book and one Persian book. She worked as reviewer for some articles in different journals.

Biography

Dr. Xiaoning Peng is currently working as a Professor and vice dean of Hunan Normal University School of Medicine. He obtained a PhD in the department of internal medicine at central south University Xiangya medical school, People’s Repulic of China. Dr. Xiaoning Peng research is mainly focused cancer genetics, microarray data analysis, genetic algorithm development and application, evidence-based medicine, tumor genome data mining and precision medicine. Dr. Xiaoning Peng is the principal investigator on National Science Foundation of China (NSFC) and pharmaceutical-funded studies and published more than 30 articles in international journals. He worked as reviewer for many articles and sits on several Editorial boards. He is Vice Chairman of Hunan Province Association for Pathophysiology, Vice chairman of Hunan provincial health statistics Committee and Academic leader of key disciplines of basic medicine of Hunan Province, People’s Repulic of China.

Biography

Evgenia Aleksandrova (more famous with her former family name Adarska) is a former patient with Breast Cancer. She has 19 years’ experience in this area as a patient consultant and navigator of patients in the health theme in Bulgaria. She is a chairwoman of Association of a cancer patient and their Friends (APOZ and Friends) in Bulgaria, the history of this NGO is 15 years. Her organization is a member of all significant cancer patient organizations as a UICC, ECPC, Europa Donna, Europa Colon, Europa Uomo, INCA and other. She has her expertise in evaluation and passion for improving the health and well-being of cancer patients and a good experience of the developing of the framework of cares of this patients. She works very well with the government structures and scientist and professional organizations. Her open and contextual evaluation model based on responsive constructivists creates new pathways for improving healthcare. She has built this model after years of experience in research, evaluation, teaching, and administration both in hospital and education institutions. The philosophy of her organization is based on the fourth-generation evaluation (Guba& Lincoln, 1989) which is a methodology that utilizes the previous generations of evaluation: measurement, description, and judgment. It allows for value-pluralism. This approach is responsive to all stakeholders and has a different way of focusing.
Her model of unmedical care of patients with BC, based on the standard of unmedical cares (2009), includes a center of Unmedical care in hospitals and specialized complex rehabilitation program of BC patient, paid by the government.
Mrs. Aleksanrova, famous as Adarska, has National and International awards for her contribution of developing of cancer care. Her last efforts are for the building of the anticancer plan on the National level.

Research Interest

Breast Cencer

Organizing Committee - Oncologists 2017

Biography

Professor Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has an H index of 57, 450+ peer-reviewed papers, 8 books, has successfully supervised 26 PhDs, and been a member of editorial boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J.Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD

Biography

Dr. Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an MD from the University of Lisbon, Portugal, and a PhD from the University of Uppsala Sweden. He made an internship at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia (USA) and at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France) and was a visiting Professor at the University of Linkoping (Sweden). He published 150 papers in professional Journals and 9 books on cancer and aging. He received the following awards: Fritz Verzar Prize (University of Vienna, Austria), “Seeds of Science”, Career Prize (Lisbon, Portugal), Dr. Honoris Causa (University of Linkoping, Sweden), Johananof International Visiting Professor (Institute Mario Negri, Milano, Italy).

Biography

Alok De has received his PhD from University of Calcutta. He is a Research Biologist at Kansas City VA Medical Center. His research focuses on to use the extract of Emblica officinalis as an alternative or adjunct therapeutic agent in helping to fight ovarian cancer . He has published more than 45 papers in reputed journals. He has been serving as reviewers of many journals and as an Editorial Board Member of Cancer Cell and Microenvironment

Research Interest

His basic research interest is in the filed of Oncology, Gynecologic cancer, Tumor biology,Cancer Cell sciences etc.

Biography

Dr. Alireza Heidari, Ph.D., D.Sc. is a Postdoctoral Research Fellow in Chemistry. He has got his Ph.D. and D.Sc. degrees form California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management and also in Nanochemistry and Molecular Structure Theory. His research interests are Biophysical Chemistry, Nanochemistry, Quantum Chemistry, Biomolecular and Vibrational Spectroscopy, Molecular Modeling and Structure, Theoretical, Computational and Mathematical Chemistry, Ab initio and Density Functional Methods. He has participated at more than fifty reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Index (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Netherlands, Russia, France, Swiss, Germany, Sweden, Spain, Portugal, South Korea, China, etc. as research fellow, sabbatical and volunteer researcher or visitor heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than ten books in Chemistry. Syne, he has been awarded more than three hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals. Hitherward, he is a member of more than one hundred reputed international academic–scientific–research institutes around the world.

Biography

Sadir Al Rawi currently is the Director of Surgical Oncology Services of Alzahra Cancer Center, Dubai and is the interim Chair of Department of surgery since October 2013. Prior to that,Alrawi was an assistant professor in the Department of Surgery/Division of Surgical Oncology at University of Florida, Jacksonville. He trained in various academic institutes
in Surgical Oncology all over including Roswell Park, Cancer institute, Buffalo, Royal Free Hospital, UC of London and Ninewells Hospital, Dundee, United Kingdom. Sadir
Al Rawi is American board certified, completed his Head & Neck fellowship and Surgical Oncology fellowship at Roswell Park Cancer institute (NCI) designated in 2006.Dr Alrawi did advanced Laparoscpic oncology training with Professor Alfred Cuschieri in Dundee 1992-1993, advanced colorectal oncology training with E Lloyd Davis in
Cornwall, England 1993-1995 and advanced surgical oncology with Professor Marc Winslett, London 1995-1996.

Research Interest

Dr Alrawi major interest is Gastrointestinal Oncology, including Esophageal, Gastric, Pancreas, Liver and colonic surgery with special interest in endocrine surgery including thyroid , parathyroid and adrenal surgery.

Biography

Mohammed Y Almaghrabi is a currently working as a Head of Radiation Oncology at Prince Faisal Cancer Centre, Saudi Arabia. He holds his Research experience from University of Ottawa Canada. He has been a recipient of many award and grants. His research experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests as a reflects in his wide range of publications in various national and international journals. His research interest includes Oncology, Radialogy, Hepatology, and Clinical Oncology etc.

Research Interest

His research interest includes Oncology, Radialogy, Hepatology, and Clinical Oncology etc.

Biography

Abdolrahman Shams Nateri Completed his doctrate degree on the genetic engineering of Picornavirus, human Parechovirus 1,at the Essex Univ. later on in the year 2001, he joined as a member of Cancer Research UK (CR-UK) London Research Institute (previously known as ICRF), where he carried out his fundamental basic-research into the links between transcription, MAPKs signaling & diseases, including the cellular/molecular biology of cancer and also rewarded with publications with top journals.In 2007, he joined as a faculty of the UoN, where he intially started as a lecturer, and was promoted as an Associate Professor,his endless passion in cancer-biology and excellent achievements boasted publications in Nature, Science, etc and more recently J Exp Med & Stem Cells.

Biography

Czerw Aleksandra, PhD, Expert in the field of health economics, organisation and management in the protection of health, medical services marketing. Assistant Professor at the Public Health Faculty of the Medical University of Warsaw. Author of numerous developments in the field of the strategic management including strategic analysis in the health protection sector. Member of the Regional and Local Analyses Centre. Co-operates with the pharmaceutical sector. Medicinal products marketing strategies consultant. Author of more than 100 national and international publications. Active member of numerous associations including: Polish Public Health Society, Polish Health Science Society, Polish Pharmaceutical Society, Polish Pharmacoecomic Society, Polish Economic Society.

Biography

José J. Jiménez-Moleón, Associate Professor of Preventive Medicine and Public Health at the University of Granada. His research subjects deal with the application of epidemiological method to the study of non-communicable diseases, including the etiology of cancer. The scientific production of his research activity stems from 12 competitive research projects (four as principal researcher) and 3 research contracts. This has resulted in 97 full-text scientific articles.

Biography

Jiri Vachtenheim received his MD from the Charles University in Prague in 1981 and PhD (1985) in the biochemistry of melanoma at the same University. His postdoctoral studies were partly performed as fellowships in Great Britain and Belgium. His long-standing interest is the biology of melanoma, focused on the role of MITF, a central melanoma transcription factor and melanoma oncogene. Further studies were performed on other tumors, especially lung cancer. He has extended the interest in cancer molecular biology and elucidates also some deregulated signaling pathways in tumors, especially the Hedgehog/GLI pathway which regulates the tumor stemness. He is a member of several American societies for cancer, biochemistry and molecular biology. He is now an Associate Professor and Head of the Department of transcription and cell signaling at the Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Biography

Dr. Wu graduated from Nanjing Normal University in 1981 (BS), and obtained his PhD degree from Columbia University, USA in 1988. He then continuously conducted his postdoctoral research at Harvard University during 1988-1991. Thereafter, he moved to Singapore as an Assistant Professor at School of Biological Sciences of National University of Singapore. Started from 2000, he worked as a full professor at University of Science and Technology of China in Hefei, Anhui. His research interests focus on molecular mechanisms for p53-regulated tumor development and regulation of non-coding RNA in tumor metabolism. He has published more than 60 research papers on international peer-reviewed journals with more than 2900 citations.

Research Interest

His research interests focus on molecular mechanisms for p53-regulated tumor development and regulation of non-coding RNA in tumor metabolism. He has published more than 60 research papers on international peer-reviewed journals with more than 2900 citations.

Biography

Dr. Wen graduated from XiamenUniversity in 1982 (BS) and obtained his PhD from University of California, Los Angeles, USA in 1988. He has over 30 years of experience in biomedical research at various academic institutions in the USA, Singapore and China. Since 2002, he has been working as a full professor at University of Science and Technology of China, with a research interest focusing on nanobiology and nanomedicine. He has published over 80 research papers on international peer-reviewed journals with more than 3000 citations and has an H-index of 37.

Research Interest

His research interests focus is basically in the field of nanobiology and nanomedicine. He has published over 80 research papers on international peer-reviewed journals with more than 3000 citations and has an H-index of 37.

Organizing Committee - Global Cancer 2017

Biography

Dr. Mane completed his PhD at the age of 28 years from The University of Bombay and postdoctoral studies from The Johns Hopkins University School of Medicine. He is the director of Yale Center for Genome Analysis, one of the most scientifically productive and accomplished Genome Centers. He has published more than 100 papers in reputed journals and has served as an ad hock reviewer of several journals. He is also one of the principle investigators of a $12 million grant from NIH/NHGRI to establish the Yale Center for Genome Analysis.

Research Interest

Biography

Jose Costa, M.D., is Professor of Pathology and Medicine at Yale University School of Medicine. A graduate of Barcelona Medical School, Dr. Costa trained in Anatomical Pathology at Colorado University (G.B. Pierce) and Washington University (P. Lacy; L.V. Ackerman). He went on to do research as a Fogarty International Fellow (1973) in the laboratory of A.S. Rabson at NCI, were he stayed to eventually become the Anatomical Pathology Branch Chief at the Clinical Center, NIH Bethesda, MD. Elected to a Chair in Pathology at the University of Lausanne (1982), he directed between 1983 and 1993 the Institut Universitaire de Patologie, developing a program of advanced diagnostics and collaborating both with the ISREC and the Lausanne Branch of the Ludwig Institute.

Biography

Dr. Karin was born in Tel Aviv, Israel and received the Bachelor of Science degree in 1975 from Tel Aviv University, with a major in Biology. In 1975 he arrived in the US and in 1979 received a Ph.D. degree in Molecular Biology from the University of California, Los Angeles. Dr. Karin followed his graduate studies with postdoctoral fellowships at the Fox Chase Institute for Cancer Research, working in the laboratory of Dr. Beatrice Mintz, and the laboratory of Dr. John Baxter at the University of California, San Francisco. Dr. Karin joined the faculty at the University of California, San Diego in 1986, where currently he is a Distinguished Professor of Pharmacology.

Research Interest

Biography

Various functions within the Immune System The laboratory is currently involved in research investigations that deal with tumor cell induction of apoptosis in cytotoxic anti-tumor effector cells, and on the mechanism of resistance of tumor cells to immunotherapy. In the first project, we have demonstrated that interaction of tumor target cells with natural killer (NK) cells resulted in the induction of apoptosis in the sensitive target cells and thereafter the induction of apoptosis in the cytotoxic effector cells. This project investigates the underlying biochemical and molecular mechanisms by which the tumor target cells trigger programmed cell death in the cytotoxic cells. The role of MHC-killer inhibitory receptors (KIR) and killer activating receptors (KAR) as well as the role of the FC-receptor in intracellular signaling pathways that result in NK apoptosis are being investigated. The second project examines the resistance of tumor cells to cytotoxicity and apoptosis by cytotoxic lymphocytes. The mechanism of resistance to Fas-ligand, TRAIL and TNF-a (effector pathways in cytotoxic lymphocytes) are being examined. In addition, we have demonstrated that resistant tumor cells can be sensitized by various agents to killing by these cytotoxic effector mechanisms. The underlying mechanisms of immunosensitization are being examined. Aside form the in vitro studies, translational in vivo studies to enhance gene/immunotherapy strategies against resistant tumor cells are also being evaluated.

Research Interest

Biography

Dr. Amy Hong Zhang, M.D., Ph. D., is currently an Assistant Professor in the Department of Pathology in University of Texas-M.D. Anderson Cancer Center in Houston, TX, specializing on breast cancer pathology. Prior to joining UT-MDACC, Dr. Zhang was an Assistant Professor in the Department of Pathology in the Baylor College of Medicine from 2006 to 2009. Dr. Zhang is an American Board certified practicing pathologist since 2003. Dr. Zhang has expertise in diagnosing breast cancer and the interpretation of the biomarkers relevant to breast cancer for patient care. Dr. Zhang is also actively participating in clinical teaching for the residents/fellows on surgical pathology. As an independent laboratory researcher, Dr. Zhang supervises research scientists and trainees on translational and laboratory research working on the characterization and development of new molecules significant for breast tumorigenesis. Her academic activities in recent years have led to a series of first author, co-author and senior author publications in recognized peer-reviewed journals.

Research Interest

As a practicing pathologist and an Assistant Professor in the Department of Pathology at M. D. Anderson with a focus on breast cancer, I have expertise in diagnosing breast cancer and the interpretation of the biomarkers relevant to breast cancer. In addition, my Ph.D. training background provided me with broader experience and interest. As an independent laboratory researcher, I work with trainees in my laboratory on the characterization and development of new molecules significant for breast tumorigenesis.

Organizing Committee - Gynecologic Oncology 2016

Biography

Dr. Hatch has been a faculty physician with UTMB for over ten years, specializing in breast and gynecological cancers. She is board certified in Radiation Oncology by the American Board of Radiology (ABR) and an active member with the American Society for Therapeutic Radiology & Oncology (ASTRO). She received her doctorate in medicine from the University of Texas Health Science Center at Houston, TX and completed her residency in radiation therapy at Baylor College of Medicine as chief resident. Before entering medical school, Dr. Hatch received her degree in engineering from Tennessee Technological University, which served as a solid foundation for the technological demands found in the field of radiotherapy.

Biography

Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human micro vascular umbilical cord endothelium for lining stents. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the “1st Place - Award for Excellence in Research” from the American Federation for Clinical Research In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemo sensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea on Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer Personalized treatment regimens.Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; commence on July 20 2014; and on the EDITORIAL BOARD of Insights in Cancer Research, and has authored and co-authored a number of scientific peer-reviewed manuscripts.She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA.

Research Interest

Research interest includes human microvascular umbilical cord endothelium and in Pharmacokinetics Oncology

Biography

Dr. Concepcion Diaz-Arrastia received her medical education from UMDNJ-Rutgers Medical School, and completed residency and fellowship training at State University of New York Downstate Medical Center in 1994. She is board certified in obstetrics, gynecology and gynecologic oncology. As a leader in the implementation of new surgical techniques like the computer-enhanced (robotic) surgery in gynecology, Dr. Arrastia was the first to report that hysterectomies could be performed using the DaVinci system in 2002. Likewise, she was the first physician in Texas to perform fertility-preserving radical vaginal trachelectomy surgery for invasive cervical carcinoma. Dr. Arrastia strongly supports early diagnosis through universal cancer screening. As Medical Director of the non-profit organization, Dia de la Mujer Latina, she has undertaken the task of bridging the gap for those women in the medically underserved communities to have easy access to cancer screening.

Research Interest

Her research interests include developing molecular signatures of cervical cancer risk. She has served as Principal Investigator for several NIH funded translational research projects in HPV-associated cervical neoplasia with the goal of developing robust prognostic and diagnostic biomarkers for refining the pathological staging of cervical carcinoma. The ultimate objectives of Dr. Arrastia’s research are personalization of care optimizing treatment outcome, while minimizing adverse reactions.

Biography

Samir A.Farghaly is a physician / Scientist- faculty member at the Medical College of Cornell University, and the New York Presbyterian Hospital/ Cornell University Medical Center, New York, NY – USA. He received his M.D degree from University College, London University and his PhD degree in molecular biology from London University. He was affiliated with Columbia University College of Physicians and surgeons/ Columbia University medical center, New York, NY. He received several clinical and research awards. He has been an invited speaker in several national and international conferences on Women’s health, Molecular genetic of female cancers, Gynecological cancer and Oncology. He is a member of several national and international societies, organizations, foundations of Women health and Cancer. He is an editor, member of editorial boards, editorial advisory boards and reviewers of several medical journals of Cancer Science & Therapy, Gynecology, Gynecological Cancer, Ovary Research, Genomics, Clinical & Experimental Obstetrics and Gynecology, and Oncology. He has published 78 articles in reputed peer review journals. He is an editor of a book on ovarian cancer published in 2011.

Biography

Farias-Eisner is currently the Chief of Gynecology and Gynecologic Oncology in the Department of Obstetrics and Gynecology at UCLA, a Principle Investigator for the National Cancer Institute (NCI) - Gynecologic Oncology Group (GOG) and the Director of the Center for Biomarker Discovery and Research at UCLA that is dedicated to the prevention and early detection of women's cancers. A graduate of UCLA where he earned a B.S. in Biochemistry, he received an M.D. at the Royal College of Surgeons in Ireland. After graduation, he was recruited to the University of Chicago University of Illinois where he obtained training in Emergency Medicine and Critical Care. He was then recruited to UCLA in 1986 to train in Obstetrics and Gynecology, and Gynecologic Oncology, and then was recruited to become a faculty member in the Department of Obstetrics and Gynecology, division of Gynecologic Oncology in 1992

Research Interest

Farias-Eisner was the first to complete the STAR (Specialty Training in Advanced Research) in the Department of Obstetrics and Gynecology at UCLA, earning a Ph.D. in Molecular Biology in 1999. Dr. Farias-Eisner has received numerous research awards and has earned UCLA's Outstanding Faculty Teaching Award in the Department of Obstetrics and Gynecology in 1993, 1996, 2004, and 2005, and the STAR Program Faculty Award in 1999 and 2000. In 2004, he was presented with the International Spirit of Life Foundation Scientist of the Year Award, and in 2005, the coveted National Association of Professors of Gynecology and Obstetrics (APGO) Outstanding Faculty Teaching Award. Recently, his peer reviewed publications include nearly 40 original articles in journals such as the Proceedings of the National Academy of Science, USA, the Journal of Biological Chemistry, the journal of Cellular Biochemistry, the journal of Gynecologic Oncology, the Journal of Neuroscience, the Journal of Neuroscience Research, and the International Journal of Gynecologic Oncology, to mention a few. Moreover, he has been selected to review articles for these very same prestigious journals. Dr. Farias-Eisner has written numerous book chapters and has been invited for more than 50 presentations, nationally and internationally.

Biography

Magdalena Klink is a graduate of Microbiology at the Faculty of Biology and Earth Sciences, University of Lodz. In 1994, she defended her doctoral thesis, and in 2005 habilitation at the University of Lodz. She annual postdoc in the College of Natural Sciences, Chungnam National University, Taejeon, Republic of Korea. Since 2004 she has been working at the Institute of Medical Biology, Polish Academy of Sciences in Lodz, now an associate professor. She was the manager of several research projects funded by KBN and Higher Education and the contractor projetu OPIE. She received awards for research including the Rector of the University of Lodz Award and Award of the Minister of Education. She completed courses on management of research projects and commercialization of research results. She is currently supervisor in three doctoral open. She is the author of 48 publications in scientific journals and editor of a monograph. For several years, she serves as editor of the journal Mediators of Inflammation. In WSZKiPZ lectures in biology with genetics.

Research Interest

Biography

Dr. Gwyn Richardson is an Assistant Professor of Gynecologic Oncology at the University of Texas Medical Branch in Galveston TX. She is also the Associate Clerkship Director for the Obstetrics and Gynecology 3rd year Medical School Clerkship. She holds the Francis Eastland Conally Professorship in Gynecologic Oncology

Organizing Committee - Cancer Diagnostics 2016

Biography

Dr. Lily Yang holds multiple NIH grants and is a translational cancer researcher who specializes in the development of novel cancer imaging and targeted therapeutic agents. she is the Professor of Surgery and Nancy Panoz Chair of Surgery in Cancer Research, Department of Surgery, Emory University School of Medicine. Her research experiences include tumor immunology, cancer stem cells, cancer gene therapy, apoptosis resistance, molecular targeted cancer therapy, nanoparticle imaging probes, and theranostic nanoparticles for targeted cancer therapy and imaging. Dr. Yang is a member of the Cancer Cell Biology Research Program at Winship Cancer Institute of Emory University, and holds professional memberships with American Association for Cancer Research, American Society of Nanomedicine, and National Cancer Institute Alliance for Nanotechnology in Cancer. Her research projects focus on the development of novel cancer nanotechnologies and imaging methods to address the major challenges in clinical oncology of early cancer detection, targeted drug delivery, overcoming drug resistance, assessment of therapeutic response using non-invasive imaging, and image-guided surgery

Research Interest

Biography

Yaguang Xi is currently working as an Associate professor of Oncologic Sciences in Mitchell Cancer Institute, USA. He received Merit award from American Society of Clinical Oncology in 2008. He also received the outstanding researcher award from Peking University, China in 2003. He is a member of Several Cancer associations like American Association for Cancer Research, American Society of Clinical Oncology and International Honor Society Beta Gamma Sigma. He is the editorial member of so many journals like Acta Pharmacologica Sinica, Journal of Integrative Oncology and Journal of Comparative Clinical Pathology Research.

Research Interest

Discovery and validation of novel biomarkers associated with tumor progression, metastasis, therapeutic response, and chemoprevention, Identification and characterization of important roles of non-coding RNA (microRNAs) in human cancer and developing novel normalization methods for microarray analysis

Biography

Clara Balsano is currently working as associate Professor of Internal Medicine at the University of L’Aquila (Italy), since 1992. She is the head of Clinical and Biomolecular Hepatology Unit at the University of L’Aquila, Department of Internal Medicine, since 1993. She is also the Head of the laboratory of “Viral and Molecular Oncology” at the Andrea Cesalpino Foundation, since 2003and the head of the laboratory “Pathology of Development”, IRCCS SR-La Pisana, since 2005. She occupied full Professor of Internal Medicine and Chair of Clinical Hepatology Unit at the University of L’Aquila, since 2007.she detached to the Ministry of Research, in 2009, to collaborate for the laboratories reconstruction, after the earthquake of the 6 April of the same year. In the same period she participated in writing the National Research Program.

Biography

Rajvir Dahiya received his PhD in the field of Experimental Medicine and Biochemistry from the Post Graduate Institute of Medical Education and Research in Chandigarh, India. He completed four years of post-doctoral fellowship training in oncology and molecular biology at the University of Chicago Pritzker School of Medicine in Chicago, IL. Dahiya joined the University of California, San Francisco (UCSF) School of Medicine in 1987 as a scientist located at the San Francisco Veterans Affairs Medical Center (VAMC). He became director of the UCSF/VAMC Urology Research Center in 1991.

Research Interest

Biography

Professor Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has an H index of 57, 450+ peer-reviewed papers, 8 books, has successfully supervised 26 PhDs, and been a member of editorial boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J.Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD

Biography

Antonino Appignani is currently working as Chief of Department of Pediatric Surgery Ospedale S.Maria della Misericordia Perugia and Chief of Department of Pediatric Surgery Santa Maria della Misericordia Hospital Perugia. He has completed his medical degree from the University of Bologna in 1974.He also acts as a secretary for various societies like S.I.C.P. Italian Society of Pediatric Surgery, S.I.U.P. Italian Society of Pediatric Urology, S.I.V.I. Italian Society of Infantile Video surgery. He has worked as Assistant professor, university Researcher in the university of Bologna. He worked as associate professor, Full professor of pediatric surgery in university of perguia.He is the Chief of Department of Pediatric Surgery Policlinico Monteluce Perugia. He has printed 280 scientific papers (national and international scientific journals) and 3 monographies. He is actively participated in more than 200 lectures and communications in national and international conferences and meetings.

Research Interest

General Surgery
Pediatric Surgery and Child Surgery
Pediatric and Child Surgery of the subject: Medical Sciences

Biography

Feng Yan, has completed her Ph.D from Yangzhou University in China. She is the vice director of Department of Clinical Laboratory in Nanjing Medical University Cancer Hospital. The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells. She has published 74 papers in SCI journals.
She was the Outstanding Medical Talents, Excellent Medical Talent and Leading Medical Talent of Jiangsu Province.

Research Interest

Biography

Mario Pazzagli is Professor of Clinical Biochemistry, Department of Clinical and Experimental Biochemical Sciences, University of Florence, Italy. Former Chair of the IFCC-C-MD commission, Advisor of the CLSI Committee on Molecular Methods; Chair of the Working Group on Personalized Laboratory Medicine of the EFLM, Co-ordinator of the FP6 EU project “External Quality Assay Programmes in Clinical Molecular Diagnostics”, partner of the FP7 EU Project SPIDIA: Standardisation and improvement of generic pre-analytical tools and procedures for in vitro diagnostics). Italian representative of the CEN/TC 140/WG 3 “Quality management in the medical laboratory”. Author of about 170 publications in International peer reviewed journals.

Research Interest

Biography

Nicola Rosa is the Professor of Department of medicine in the University of Salerno. He has completed his degree in medicine and surgery from the University of Naples and worked as a director of University Department of Ophthalmology at the University of Naples. He worked as the Coordinator of the PhD in "Issues and optical clinics of refractive defects and their surgical correction" (XVIII cycle).He is the Board Member of Italian Society of Ocular Trauma and Ergoftalmologia (Sieto) and Bell Glaucoma Association (ASCG).He has received "Masters of Ophthalmology" in 1991 and "Semiotics eyepiece" in 1994. From 'American Academy of Ophthalmology' s "Achievement Award" in 2006 and "Best Poster Award in 2007 and in 2008.He was a member of the Scientific Committee, Invited speaker and moderator at numerous Congresses and Symposia internationalized.He is the author of more than 400 publications.He has given lectures at the Universities of Vienna (Austria), Naples, Padua, Pisa, Rome, Ferrara, Regensburg, Hamburg.

Research Interest

Biography

Tibor Tot, associate professor of pathology at the University of Uppsala and head of Laboratory Medicine Dalarna, Sweden, is faculty member of the breast pathology arm of the European School of Pathology (ESP), and scientific director in the European School of Oncology Certificate of Competence in Breast Cancer program. Publications: 6 textbooks, 20 book chapters, and 80 journal articles mostly on radiological – pathological correlation of breast diseases. He is repeatedly invited speaker on international congresses, member of the European Working Group for Breast Cancer Screening Pathology and past chair of the Working Group for Breast Pathology of the ESP.

Research Interest

Biography

Prof Dr med Gamal Abdul Hamid has received his PhD in hematology-oncology from faculty of medicine (Caral Gustav Carus),University of Dresden during the period of 1988- 1993. Currently he is working as director of Aden Oncology Center and head of hematology and clinical laboratory in Faculty of Medicine, University of Aden. He has successfully completed his administrative responsibilities as general secretary of Yemen Cancer Society and founder of Aden cancer registry. He is serving as an editorial member of several journals like Yemen Oncology newsletter, Journal of pathobiology and toxicology. He has authored or co-authored many articles in a great variety of journals and has delivered lectures at many conferences and institutions in Yemen and internationally and referee for national and international journals. He is member of ESMO, ASCO, INCTR and Panarab Oncology.

Research Interest

Organizing Committee - Cancer Summit 2015

Biography

Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of natural bioactive and biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar’s main research objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated "double targeted nano-bullet nanocapsules" with natural anti-tumour proteins which specifically target cancer cells.

Research Interest

Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases. We also vested the molecular diagnosis including role of a non-invasive exosomes in blood, inflammatory sites and cancer tissues. Our research focused on cancer and inflammatory autoimmune diseases aims to investigate the underlying mechanisms involved in apoptosis, autophagy and inflammation by targeting the production of cytokines, chemokines, oxygen radicals and matrix metalloproteinase. Our research also aims to investigate the nanotherapeutics encapsulating peptides, LNA modified aptamers/miRNAs/siRNA in vivo models. We have made significant progress in field of ocular drug delivery and microfluidic and Lab-on-a-Chip devices techniques for cancer cells as well as stem cell capture, disease specific biomarkers and exosomes.

Biography

K.N. Leung graduated with a B.Sc. Degree in Biochemistry (First Class Honors) from The Chinese University of Hong Kong (CUHK) and obtained a Ph.D. Degree in Microbiology and Immunology from the John Curtin School of Medical Research, Australian National University. After two years of postdoctoral work at the Pathology Department of the University of Cambridge, he returned to the CUHK as a Lecturer in the Department of Biochemistry in 1983. K.N. Leung is now a Professor in the School of Life Sciences, CUHK and was appointed as Assistant Dean of the Faculty of Science in 2007, and then Associate Dean (Education) of the Faculty of Science in 2014. He was the chairman of the Hong Kong Society for Immunology from 2000-2002. He has served the Editorial Boards of several international journals and as a peer reviewer for 15 journals. He has over 30 years of experience in teaching and research in Immunology and Cancer Biochemistry. His main research interests include immunopharmacological studies of food components, natural products and Chinese medicinal herbs, cancer immunotherapy, and molecular studies of leukemic cell proliferation, differentiation and apoptosis.

Research Interest

His main research interests include immunopharmacological studies of food components, natural products and Chinese medicinal herbs, cancer immunotherapy, and molecular studies of leukemic cell proliferation, differentiation and apoptosis.

Biography

Rupinder K Kanwar completed her PhD from PGIMER, India. Since then she has worked in India, New Zealand and Australia, in a variety of positions supporting and building new research programs related to interdisciplinary research, international collaborations and large-scale initiatives ranging from biomedicine to nanomedicine. She has 15 years’ experience in drug discovery targeting cancer and chronic inflammation, and delivered both academic and industry-oriented research with 75 peer reviewed publications. Dr Kanwar is a key inventor in more than 20 published and live patents/ applications. Her current research focuses on targeting molecular pathogenesis of chronic inflammatory diseases and cancer with nanodrug and nanodiagnostic developments. At Deakin University, she is providing leadership to her research team on deciphering novel molecular targets for protein biodrugs to treat cancer and cardiomyopathy. She serves as an editorial advisory board member and reviewer of several international journals. Dr Kanwar has been invited as a speaker, and chair in national & international conferences, and her research presentations won awards at conferences

Research Interest

Biography

Zhi Ping(Gordan)Xu obtained his PhD degree in April 2001 from the National University of Singapore, and then did his postdoctoral research at the University of North Texas. In Sept 2003, he joined UQ as a research fellow, and then he was continuously awarded the ARC Australian Postdoctoral Fellowship (APD 2005), the ARC Australian Research Fellowship (ARF 2008) and the ARC Future Fellow (2012). Since 2005, he has attracted over $7 million in funding including ARC discovery project grants, ARC linkage project grant, ARC LE grant and NHMRC grant, and many internal UQ grants to support his research in nanomateials and biomedicine. His outstanding research has been also recognised by the UQ prestigious award in 2009 - UQ Foundation Excellence Research Award, and also the UQ Vice-Chancellor's Senior Research Fellowship in 2013.

Research Interest

Cancer, Nanotechnology, Nanomaterials

Organizing Committee - Breast Cancer-2015

Biography

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair
of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of
Pathology and Laboratory Medicine at Shands Jacksonville.She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the
“International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on
Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society
for Breast Health.” She has been named as one of the Top Doctors in
America and one of the 20 Top Professors in Oncology at an international level. Dr. Masood is a patient
advocate, a partner in community affairs and an accomplished artist and gourmet chef.

Research Interest

She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the
“International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on
Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society
for Breast Health.”

Biography

Marie Wood, MD is professor of medicine, deputy director of the hematology/Oncology Division and director of the Familial Cancer Program. She is a member of the ASCO Prevention Subcommittee and Vice Chair for the CALGB/AIIiance Prevention Committee. Dr. Wood's research focuses around cancer genetics and breast cancer prevention. She has done studies on the barriers to utilization of cancer genetics by primary care providers and recent work has focused on the definition of an adequate family history for oncology professionals. Dr. Wood has received national and local funding to evaluate the link between breast density and vitamin D in women at risk for breast cancer. She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

Research Interest

She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

Biography

Yvone Paterson is Professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, USA. As a Professor of Microbiology, Paterson is an active educator and trainer and is the PI of several training grants and programs. Her research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system. She has pioneered the application of this organism in vaccine development for over 20 years. Her laboratory was the first to show that this bacterium could be genetically engineered to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells, the first to show that it could provide protective immunity against viral challenge and the first to apply the technology for the immunotherapy of cancer. In partnership with Advaxis Inc., a company she founded in 2002, the Listeria based technology is now in a number of clinical trials. Overall, these trials have shown that Listeria based immunotherapeutics are safe to use in humans and result in significantly prolonged survival and, in some cases, complete and partial remissions.

Research Interest

Yvone Paterson research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system.

Biography

Professor Khan is Professorial Fellow at the Department of Medicine, University of Melbourne; and School of Public Health and Preventative Medicine, Monash University. She is the Director of the Rehabilitation Services at the Royal Melbourne Hospital. She completed her specialist training in Rehabilitation Medicine in 2000 and ‘Doctor of Medicine’ in 2009. She is a Representative for the Western Pacific Region WHO, ICF Research Branch; Executive member of the WHO International Disaster Committee and Task Force Lead, Committee for Rehabilitation Disaster Relief, ISPRM. She currently holds 9 international academic research appointments in Europe and US. She has a leadership role in rehabilitative care and research, and has published over 250 scientific papers (including 14 Cochrane reviews, 12 book chapters), and is invited speaker at national and international conferences (over 50 presentations in last 5 years).

Research Interest

he has a leadership role in rehabilitative care and research, and has published over 250 scientific papers (including 14 Cochrane reviews, 12 book chapters), and is invited speaker at national and international conferences.

Biography

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center. she has done Degree-Granting Education in 1980 at University of Ankara School of Medicine, Ankara, Turkey.

Research Interest

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center.

Biography

P Raghu Ram is amongst the few in the World to have acquired prestigious FRCS from all four Royal Colleges in British Isles (London, Edinburgh, Glasgow, Ireland)
& FACS from American College of Surgeons. Having obtained First Place in MS Postgraduate Examination, he completed Subspecialty training in Breast Surgery
at world renowned Centers of excellence in the UK. He is the youngest ever recipient of the International Gold Medal (2013) in the 508 years history of the Royal
College of Surgeons of Edinburgh.

Research Interest

He is the youngest ever recipient of the International Gold Medal (2013) in the 508 years history of the Royal
College of Surgeons of Edinburgh.

Biography

Zeina Nahleh is currently Professor of Internal Medicine and Chief of the Division of Hematology-Oncology at the Texas tech Health Sciences Center in El Paso, TX. She is also Co-Director of the Texas Tech Garbar Breast Care Center and Chairperson of the University Medical Center (UMC) Cancer Committee. DR Nahleh was previously employed as Associate Professor and Co-Leader of the Breast Cancer Multidisciplinary team at the Wayne State University- Barbara Ann Karmanos Cancer Institute, aNational Cancer Institute(NCI) - designated Cancer Center. Dr Nahleh’ s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients. Dr Nahleh is a principal investigator in the Southwest Oncology Group (SWOG) and a member of the NCI- Neoadjuvant and Metastatic breast committees. She is also a member of the American Society of Clinical Oncology and the American College of Physicians. Dr Nahleh has received numerous awards including the Barbara Ann Karmanos‘sHero of Breast Cancer Award, and the TTUHSC –EP Dean’s Excellence in Research Award. She has authored over 50 articles, books and book chapters in the field of cancer and breast cancer research. She has presented in major national and international cancer meetings and serves on the editorial board of numerous world -renowned medical journals.

Research Interest

Nahleh’s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients.

Biography

Alahari Suresh obtained his Bachelor of Science in Biology and Master of Science in Human Genetics from India in 1983 and 1986 respectively. His Ph.D. in Molecular Biology was awarded by Drexel University, Philadelphia in the year 1994. From 1994 to 1998, Dr. Alahari did a post-doctoral fellowship at the University of North Carolina at Chapel Hill. Since 1998, he has been a faculty member at the University of North Carolina and in 2004 joined the LSUHSC as Associate Professor of the Department of Biochemistry. During his tenure at the University of North Carolina, he discovered a novel protein that he termed, Nischarin. Dr. Alahari has published several papers describing the function of Nischarin. He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

Research Interest

He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

Biography

Dr. Henry Lynch established Creighton's Hereditary Cancer Prevention Clinic in 1984, an
interdisciplinary clinic where families can find information and services related to all hereditary
cancers. Dr. Lynch had the idea to look at cancer from a genetics perspective (he postulated
that cancer could be hereditary) rather than focusing exclusively from an environmental point
of view (which at the time was the only acceptable cause for cancer in the medical circles). This
idea became the main focus of his research for years to come.
Dr. Lynch developed what are today regarded as the cardinal principles of cancer genetics: early
age of onset of the disease, specific pattern of multiple primary cancers, and Mendelian
patterns of inheritance in hundreds of extended families worldwide.

Research Interest

Dr. Lynch developed what are today regarded as the cardinal principles of cancer genetics: early
age of onset of the disease, specific pattern of multiple primary cancers, and Mendelian
patterns of inheritance in hundreds of extended families worldwide.

Biography

Yan-gao Man holds a medical doctor degree in Western Medicine and Master degree in Cell Biology and Microbiology from China, and a PhD in Cell Biology and Anatomy from USA. He received postdoctoral training in Cancer Biology at the American National Cancer Institute. After receiving his PhD in 1998, he has authored and co-authored over 200 published scientific and 46 non-scientific articles, and received 18 research grants and 3 patent certificates. He served as the Director of Gynecologic and Breast Research Laboratory of Armed Forces Institute of Pathology and American Registry of Pathology from 1995 to 2011. Currently, he serves as the Director of Research Laboratory and International Collaboration at Bon Secours Cancer Institute. He is also the editor-in-chief of a SCI (Journal of Cancer) and four newly launched international medical journals. His main research interest focuses on the mechanism of cancer invasion and metastasis. He is the author of the world most updated theories for cancer invasion and metastasis. His theory of cancer invasion has been regarding as more compatible with existing data than the traditional theory. Among all major theories of cancer metastasis, his theory is the only one that can explain all steps of metastasis.

Research Interest

Yan-gao Man main research interest focuses on the mechanism of cancer invasion and metastasis.

Biography

Dr Azim is a Professor of Clinical Oncology and immediate past chairman of the Department of Clinical Oncology, Faculty of Medicine, Cairo University.
He is the president of the Cairo Oncology Center, one of the largest private Cancer centers in the Middle East region.
Dr Azim chairs the scientific committee of the NCCN Middle East chapter and is a member of numerous societies, including the ASCO, ASH, ESMO, ASTRO and the European Blood and Marrow Transplantation Society.
He has been principal investigator for many multicenter clinical trials and has published more than 80 papers and he was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006).
Dr Azim serves as a referee for the Annals of Oncology Journal, THE BREAST, BMC Cancer, Chemotherapy journal , Advances in Cancer Research & Treatment, Journal of the Egyptian National Cancer Institute, and the Chinese Clinical Oncology Journal.

Research Interest

He has been principal investigator for many multicenter clinical trials and has published more than 80 papers and he was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006).

Biography

Robert-Alain Toillon has completed his PhD at the age of 28 years from Lille University and postdoctoral studies from Université Libre de Bruxelles. He is the director of “Neurotrophin signaling and therapy resistance” team in INSERM U908 lab. He was hired as cell biology professor of Lille University in 2013 and published more than 30 papers in reputed journals.

Research Interest

He was hired as cell biology professor of Lille University in 2013 and published more than 30 papers in reputed journals.

Biography

Jin Cheng has completed his MD and PhD from Beijing Capital Medical University and Paris University XIII in 1986 and 1994, respectively. Following his postdoctoral training at Fox Chase Cancer Center in Philadelphia, he was recruited by Moffitt Cancer Center as an assistant professor in 1997. Currently, he is professor and interim chair of Deportment of Molecular Oncology at Moffitt Cancer Center. He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

Research Interest

He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

Biography

Dr. Kumar received his Ph.D. degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. Dr. Kumar’s research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, Dr. Kumar has also served as Editorial Board member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Research Interest

Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies.

Biography

Merdan Fayda is an associate professor at Istanbul University, Institute of Oncology, Dept. Of Radiation Oncology. He has been working in the field of radiation oncology since 1999, when he began his education at Istanbul University‘s Institute of Oncology Dept. of Radiation Oncology. Since then, Dr. Fayda has been involved with the Italian Hospital Dept. of Radiation Oncology, Gulhane Military Medical Academy, Dept. of Radiation Oncology, Kocaeli University Faculty of Medicine, Department of Radiation Oncology, and his current affiliation with Istanbul University Institute of Oncology, Department of Radiation Oncology. Dr. Fayda is a member of the Turkish Society of Radiation Oncology, ASTRO and ESTRO. He has several publications which include his thesis on Patient and treatment related factors affecting locoregional recurrence after post-mastectomy adjuvant radiotherapy’, Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer and his most recent publication of The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.

Research Interest

Dr. Fayda is a member of the Turkish Society of Radiation Oncology, ASTRO and ESTRO. He has several publications which include his thesis on Patient and treatment related factors affecting locoregional recurrence after post-mastectomy adjuvant radiotherapy’, Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer and his most recent publication of The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer

Biography

Professor Weightman is an experimental physicist with a track record in developing novel instruments. He was a co-applicant on the proposal to construct the ALICE machine which is an energy recovery linear accelerator, the first of its kind in Europe and the only one in the world equipped with a terahertz beamline designed for studies of cancer. ALICE is now operational and Weightman is leading a collaborative programme involving academic scientists and clinicians in exploiting the potential of ALICE for cancer research.

Research Interest

Weightman is leading a collaborative programme involving academic scientists and clinicians in exploiting the potential of ALICE for cancer research.

Be a member and support us

Follow us

Authorization Policy

By registering for the conference you grant permission to Conference Series LLC Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.